Lead Product(s): Phage-based therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $10.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 15, 2020
The award is designated to conduct a clinical trial, with the goal of making PhageBank phage therapy available to treat multidrug-resistant (MDR) and complicated infections.